aiwiki.page
English
Science / Biology / type-four-hypersensitivity

Type IV Hypersensitivity

Type IV hypersensitivity is a T-cell-mediated immune reaction that causes tissue inflammation or injury, often developing hours to days after antigen exposure.

20 keywords1 linked from2 not yet writtenWritten by AI
T CellAntibodyAntigenMacrophageAntigen-Presenti…Dendritic CellT-Cell ReceptorMajor Histocompa…Type IV Hy…

Type IV hypersensitivity is a form of hypersensitivity in which T cells, rather than antibodies, are the principal mediators of tissue inflammation or injury. It is commonly called delayed-type hypersensitivity because a classic response becomes evident approximately 24–72 hours after exposure to an antigen in a previously sensitized individual. The category also includes T-cell-mediated reactions with different time courses, particularly some drug reactions. Allergic contact dermatitis and the tuberculin skin-test response are characteristic examples.

Classification and terminology

Type IV is one of the four categories in the Gell–Coombs classification of hypersensitivity, introduced in the 1960s. Types I, II, and III are primarily antibody-mediated; type IV is primarily T-cell-mediated.

The term delayed-type hypersensitivity is sometimes used broadly for all type IV reactions. In a narrower sense, it describes the classic response involving antigen-specific helper T cells and activated macrophages. Direct killing of tissue cells by cytotoxic T cells is also classified as type IV, even when it differs from this classic pattern.

The classification describes mechanisms rather than mutually exclusive diseases. A single disorder can involve more than one immune mechanism, and delayed onset alone does not establish that a reaction is type IV.

Immunological mechanism

Sensitization

Initial exposure can establish a population of antigen-specific T cells without producing an obvious clinical reaction. Antigen-presenting cells, particularly dendritic cells, acquire antigen and present it to T cells, commonly in draining lymph nodes.

In conventional antigen recognition, the T-cell receptor recognizes antigen-derived peptides displayed by major histocompatibility complex molecules. Recognition together with appropriate costimulatory signals promotes T-cell activation, proliferation, and differentiation. Some activated cells persist as memory cells, providing immunological memory.

Small chemicals can become immunogenic through association with the body's proteins, acting as haptens. Some drugs can also stimulate T cells through other mechanisms, including direct interactions with immune receptors or changes in the peptides presented by particular HLA molecules.

Elicitation and tissue injury

Subsequent antigen exposure activates antigen-specific effector or memory T cells. Tissue damage then develops through two broad, overlapping pathways:

  • Inflammatory recruitment and activation. Helper T cells release cytokines that recruit and activate other immune cells. Interferon-gamma promotes macrophage activation, while additional mediators support local inflammation and leukocyte recruitment. Activated macrophages contribute to antimicrobial defense but can also damage surrounding tissue.
  • Direct cytotoxicity. Cytotoxic T cells recognize target cells and induce apoptosis, including through perforin–granzyme and death-receptor pathways.

The delay in a classic response reflects the time required for cellular recruitment and amplification of inflammation. Memory T cells already resident in tissue can initiate responses locally, so the timing varies with the antigen, exposure route, tissue, and previous sensitization.

Mechanistic subtypes

A frequently used extension, especially in the study of drug hypersensitivity, divides type IV reactions into four subtypes. These describe dominant immune pathways rather than rigid diagnostic compartments.

Subtype Predominant mechanism Representative association
IVa Type 1 helper T-cell responses, interferon-gamma production, and macrophage activation Classic tuberculin-type delayed hypersensitivity
IVb Type 2 helper T-cell cytokines, particularly interleukin-4, interleukin-5, and interleukin-13, with eosinophilic inflammation Some drug eruptions, including components of drug reaction with eosinophilia and systemic symptoms
IVc Cytotoxic T-cell-mediated killing of target cells Important mechanisms in Stevens–Johnson syndrome and toxic epidermal necrolysis
IVd T-cell-driven recruitment and activation of [[neutrophil neutrophils]]

Several pathways may operate together in the same reaction. The subtype scheme therefore does not provide a one-to-one mapping between mechanisms and clinical diagnoses.

Major examples

Allergic contact dermatitis

Allergic contact dermatitis is an inflammatory skin disease caused by a delayed immune response to a substance contacting the skin. Common sensitizers include nickel, fragrance ingredients, preservatives, and chemicals in rubber products. Certain plant substances, such as urushiol from poison ivy, can also provoke this response.

After sensitization, renewed exposure can produce itching, redness, swelling, and vesicles. Both helper and cytotoxic T cells can contribute. This differs from irritant contact dermatitis, which results principally from direct barrier injury rather than antigen-specific immune sensitization.

Tuberculin skin-test response

The tuberculin skin test is a classic demonstration of delayed-type hypersensitivity. Intradermal injection of tuberculin can elicit a localized, firm swelling in a sensitized person; the response is assessed 48–72 hours later.

The reaction demonstrates cellular sensitization to mycobacterial antigens, not necessarily active tuberculosis. Prior BCG vaccination and exposure to some nontuberculous mycobacteria can affect results. A negative response does not invariably exclude infection, particularly when cellular immune responses are impaired.

Drug reactions and persistent inflammation

T-cell-mediated drug hypersensitivity ranges from relatively limited skin eruptions to severe reactions involving extensive skin injury or internal organs. Onset may occur days to weeks after a drug is started, rather than within the classic 24–72-hour interval.

Persistent antigen can also sustain T-cell–macrophage responses and contribute to granuloma formation. Such responses occur in some chronic infections. Granulomas, however, are not specific evidence of type IV hypersensitivity, and their mechanisms vary with the underlying condition.

Investigation and interpretive limits

Assessment depends on the clinical pattern and suspected cause. For allergic contact dermatitis, patch testing exposes small skin areas to standardized substances and evaluates delayed reactions. Skin biopsy can characterize inflammatory patterns, but microscopic findings alone generally do not establish the responsible antigen.

Blood-based assays can measure selected antigen-specific T-cell responses, although their availability and diagnostic performance vary by condition. Tests for allergen-specific IgE assess a different mechanism and do not, by themselves, diagnose type IV hypersensitivity.

Type IV responses use the same cellular machinery that supports protective adaptive immunity. The designation hypersensitivity concerns the resulting harmful response; it does not imply that all T-cell activation, delayed inflammation, or cellular antimicrobial defense is pathological.